

Cytovia Therapeutics aims to broaden the application and accessibility of transformational cell therapies by matching cancer patients with the optimal modality. Cytovia's broad portfolio consists of a unique set of platforms comprised of proprietary multi-specific NK cell engagers and off-the-shelf, iPSC-NK / CAR-NK cells. Cytovia's wholly-owned pipeline includes products with first-in-class potential created by plugging validated targets in cutting-edge yet clinically validated NK engager and CAR-NK platform technologies.

Key Selling Points and Highlights

- Cytovia is the only NK company developing Universal NK cells, CAR NK cells and NK engager BisAb
 - Cytovia's iPSC NK platform includes secure GMP iPSC source, best-in-class TALEN® gene editing and CARs, proprietary differentiation, novel expansion and efficient cryopreservation
 - FLEX-NK46® platform (NKp46 bispecific Abs) has demonstrated manufacturability and in vivo functionality with key advantages including low immunogenicity, excellent stability and long half life
- Differentiated pipeline with multiple first-in-class therapeutic candidates that have \$1bn+ peak sales potential in areas of strong unmet medical need for hematological and solid tumors
 - Up to Three INDs for Talen® gene edited iPSC derived CAR NK in 2022
 - First iPSC derived Universal NK cell IND in 2021 followed by IND for First in Class GPC3 NK engager BisAb
- Strong wholly-owned and exclusively-licensed IP portfolio claiming bispecific NK cell engagers and iPSC-NK / CAR-NK cell therapies
- R&D Center of Excellence in Natick, MA and GMP Manufacturing Plant (Summer 2021)
- World class scientific partnerships with industry and academia
 - R&D collaboration with Cellectis to develop TALEN® gene edited iPSC NK and CAR-NK cells
 - Sponsored research and exclusive licensing agreements with UCSF, New York Stem Cell Foundation, National Cancer Institute, Hebrew University and INSERM
- Seasoned Management team and Board of Directors with broad biopharma experience

Differentiated iPSC Cell Technology

		Autologous CAR-T	Allogeneic CAR-T	Donor-Derived CAR-NK	iPSC-Derived CAR-NK	Cytovia
Safety	GvHD	Low	TBD	Low	Low	Low
	CRS or Neurotoxicity Risk	High	High	Low	Low	Low
Manufacturing	Off-the-shelf Product	-	+	+	++	++
	Cost of Manufacturing	+++++	++	++	+	+
	Ease of Gene Editing	++	+	++	+++++	+++++
	Master Cell Bank	-	+	+	+++	+++
	Homogenous Product	+	+	+	+++	+++
	Batch to Batch Variation	Yes	Yes	Yes	No	No
Efficacy	Multiple Dosing	No	TBD	Yes	Yes	Yes
	Persistence	+++++	++	+	++	+++
	CAR-Independent Tumor Cytotoxicity	-	-	+	+	+
	Improved Activity Against Solid Tumor	-	-	-	-	+

Unique Targets Amongst iPSC-CAR-NK Companies

		Cytovia	Century	Fate
Blood Cancers	CD19		✓	✓
	BCMA		✓	✓
	CD38	✓		
Solid Tumors	EGFR	✓		
	GPC3	✓		
	MICA			✓

Pipeline Overview

	Product	Target	Indications	Target IND
Universal iPSC Cells	CYT-100	Non-Engineered	HCC, AML, Liquid & Solid Tumors	2021
	CYT-150	Engineered	Liquid & Solid Tumors	2022
NK Engager Antibodies	CYT-303	NKp46-GPC3	HCC, Solid Tumors	2021
	CYT-338	NKp46-CD38	Multiple Myeloma, Lymphoma	2022
iPSC-CAR-NK	CYT-501	EGFRvIII EGFR wt	GBM, Solid Tumors	2022
	CYT-503	GPC3	HCC, Ovarian, Solid Tumors	2022
	CYT-538	CD38	Multiple Myeloma, Lymphoma	2022

Comparable Companies

(\$ in millions, except per share data)

Company	Share Price	% of 52 wk. high	Market Cap	Net Cash	TEV	2025E Rev.	TEV / 2025E Rev.
Fate Therapeutics	\$102.45	85%	\$9,391	\$489	\$8,902	\$489	18.2x
Nkarta	\$53.45	68%	\$1,742	\$330	\$1,412	\$59	24.1x
Mean		76%	\$5,567	\$409	\$5,157	\$274	21.1x

Note: Market data as of 02/12/21 per Capital IQ.

Management Team & Board of Directors

Management	Position
Daniel Teper, PharmD	Founder / Chair & CEO
Wei Li, PhD	Chief Scientific Officer
Robert Salcedo	Head of Manufacturing
Armin Rath, PhD	Business Development
Dan Chiche, MD	Clinical Development
Sophie Badré, MS	Corporate Affairs
Kaouthar Lbiati, MD	Product Strategy
Anna Baran-Djokovic, LLM	Investor Relations
Board Members	Affiliations
Leila Alland, MD	AffiMed, AstraZeneca, BMS, PMV Pharma
Laurent Audoly, PhD	Kymera, MedImmune, Merck, Pfizer, Pieris
Michael Friedman, MD	Celgene, City of Hope, FDA, Pharmacia
Massimo Radaelli, PhD	Ariai, Dyax, NovaBay, Noventia Pharma
Tom Robinson	Boston Scientific, Cardinal, Cynosure
Gilles Seydoux, PharmD	GSK, P&G, Wyeth
Jane Wasman, JD	Acorda, New York Bio, Rigel, Sellas